Fluidigm Announces $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors and Rebranding to Standard BioTools Inc.

Mission to Reinvigorate Growth through Optimization of Mass Cytometry and Microfluidics Platforms and Portfolio Expansion via Strategic Acquisitions

Read more at globenewswire.com